Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 9/20 | 0.49 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | TGM6 | O95932 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859559 | 0.85 | DPP4 (0.66) | DPP8DPP9DPP4DPP7ITGB3 | |
| SCHEMBL2859552 | 0.85 | DPP4 (0.66) | DPP8DPP9DPP4DPP7ITGB3 | |
| SCHEMBL10077062 | 0.83 | TGM2 (0.69) | DPP8DPP9ITGB3ITGA2BTGM2 | |
| SCHEMBL2858566 | 0.81 | DPP8 (0.56) | DPP8DPP9DPP4DPP7TGM2 | |
| SCHEMBL2858562 | 0.81 | DPP8 (0.56) | DPP8DPP9DPP4DPP7TGM2 | |
| SCHEMBL2854140 | 0.77 | TLR2 (0.53) | DPP8DPP9DPP4DPP7ITGB3 | |
| SCHEMBL2854141 | 0.77 | TLR2 (0.53) | DPP8DPP9DPP4DPP7ITGB3 | |
| SCHEMBL13041082 | 0.77 | KLK7 (0.57) | DPP8DPP9ITGB3ITGA2BTGM2 | |
| SCHEMBL18560008 | 0.77 | KLK7 (0.57) | DPP8DPP9ITGB3ITGA2BTGM2 | |
| SCHEMBL10074998 | 0.77 | DPP4 (0.53) | DPP8DPP9DPP4DPP7ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | DPP8 127/4885DPP9 97/4885DPP4 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.